First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.

Özgüroğlu, MUSTAFA; Kilickap, Saadettin; Sezer, Ahmet; Gümüş, Mahmut; Bondarenko, Igor; Gogishvili, Miranda; Nechaeva, Marina; Schenker, Michael; Cicin, Irfan; Ho, Gwo; Kulyaba, Yaroslav; Zyuhal, Kasimova; Scheusan, Roxana-Ioana; Garassino, Marina; He, Xuanyao; Kaul, Manika; Okoye, Emmanuel; Li, Yuntong; Li, Siyu; Pouliot, Jean-Francois; Seebach, Frank; Lowy, Israel; Gullo, Giuseppe; Rietschel, Petra

doi:10.1016/s1470-2045(23)00329-7

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.

Özgüroğlu M., Kilickap S., Sezer A., Gümüş M., Bondarenko I., Gogishvili M., ...More

The Lancet. Oncology, vol.24, pp.989-1001, 2023 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 24
Publication Date: 2023
Doi Number: 10.1016/s1470-2045(23)00329-7
Journal Name: The Lancet. Oncology
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, MEDLINE
Page Numbers: pp.989-1001
Istanbul University-Cerrahpasa Affiliated: No

Abstract

In the Wess-Zumino gauge, supersymmetry transformations become non-linear and are usually incorporated together with BRS transformations in the form of Slavnov-Taylor identities, such that they appear at first sight to be even non-local. Furthermore, the gauge fixing term breaks supersymmetry. In the present paper, we clarify in which sense supersymmetry is still a symmetry of the system and how it is realized on the level of quantum fields.